Candid Therapeutics (Alumni)

UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers

Prometheus, Jeff Bezos’ AI startup, is now worth $41 billion

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Alumis, Inc. (Alumni)

Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval

Foresight Diagnostics (Alumni)

Natera acquires Foresight Diagnostics for up to $450M

Avenzo Therapeutics (Alumni)

Avenzo Raises $60M Series B

Medical Device Network

Foresight and Roche sign licensing deal for PhasED

Orange County Business Journal

CG Oncology Completes Enrollment for Phase 3 Study

Xaira Therapeutics

Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell

RayThera

RayThera launches with $110 million to advance immunology pipeline